ECEESPE2025 ePoster Presentations Pituitary, Neuroendocrinology and Puberty (220 abstracts)
Age-related differences in clinical features of central precocious puberty: insights from a portuguese cohort
Ana Leite 1,2 , Sofia Ferreira 3 , Brígida Robalo 4 , Ana Monteiro 5 , Daniela Amaral 6 , Francisco Caetano 7 , Filipa Espada 8 , Suzana Figueiredo 9 , Joana Caetano 10 , Teresa Borges 11 , Elisa Galo 12 & Catarina Limbert 7,13
1Unidade Local de Saúde Gaia e Espinho, Vila Nova de Gaia, Portugal; 2Clínica CUF - São João da Madeira, São João da Madeira, Portugal; 3Unidade Local de Saúde de São João, Porto, Portugal; 4Unidade Local de Saúde Santa Maria, Lisboa, Portugal; 5Unidade Local de Saúde de Amadora/Sintra, Lisboa, Portugal; 6Hospital Lusíadas, Lisboa, Portugal; 7Unidade Local de Saúde São José - Hospital Dona Estefânia, Lisboa, Portugal; 8Unidade Local da Saúde de Matosinhos, Matosinhos, Portugal; 9Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal; 10Unidade Local de Saúde de Coimbra, Centro Hospitalar e Universitário de Coimbra - Hospital Pediátrico, Coimbra, Portugal; 11Unidade Local da Saúde de Santo António, Centro Materno-Infantil do Norte, Porto, Portugal; 12Hospital da Luz, Lisboa, Portugal; 13NOVA University of Lisbon, NOVA Medical School, Comprehensive Health Research Center (CHRC), Lisbon, Portugal
JOINT2191
Background: Central precocious puberty (CPP) presents age-dependent diagnostic and therapeutic challenges. This study aims to analyze the clinical, laboratory, and radiological features of CPP across age clusters and evaluate their impact on treatment decisions.
Methods: A prospective multicenter study (2014-2024) analyzed 591 CPP patients from a Portuguese national database, stratified into three age clusters based on symptom onset: cluster I (≤3 years), cluster II (4–6 years), and cluster III (≥6.1 years). Clinical, hormonal, and treatment data were compared across clusters.
Results: CPP diagnoses increased markedly during 2020–2021, driven primarily by cluster III (P = 0.003), decreasing thereafter. Females were predominant in all clusters (539; 91%), although cluster III had 40 from the 52 males, there was no sex incidence significant difference among clusters. Secondary causes were more prevalent in cluster I (45%, P <0.001). Weight-SDS, Height-SDS and BMI-SDS were similar among clusters. As expected, growth velocity was higher in cluster I (P = 0.011), while bone age advancement was significantly lower (P <0.001). Basal LH and FSH levels were highest in cluster III (P = 0.004, P = 0.009), whereas stimulated FSH peaked in cluster I (P <0.001) and stimulated LH peaked in all clusters. Stimulated LH/FSH ratio was lower on cluster I (p= 0.002). IGF1 and IGF1-SDS were elevated across all clusters, with no significant age-related differences. Treatment duration was longer in cluster I (5.7±0.8 years, P= 0.001), however they ended treatment with younger bone age (10.8±1.9 years; P = 0.019). Despite these differences, age at menarche was similar across clusters and age of menarche 0.5±1.9 years earlier than their mothers.
Conclusion: Age clustering highlights critical differences in CPP presentation, influencing diagnostic and therapeutic approaches. Earlier treatment intervention, although associated with longer treatment duration, did not affect menarche timing. Future studies are needed to investigate the apparent influence of external factors, such as the COVID-19 pandemic, on CPP incidence.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more